Compare BBN & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBN | CERT |
|---|---|---|
| Founded | 1983 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 860.9M |
| IPO Year | N/A | 2020 |
| Metric | BBN | CERT |
|---|---|---|
| Price | $16.17 | $6.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 158.4K | ★ 3.9M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 6.90% | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | N/A | $4.18 |
| Revenue Next Year | N/A | $5.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $15.38 | $5.19 |
| 52 Week High | $17.45 | $14.03 |
| Indicator | BBN | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 53.90 |
| Support Level | $16.11 | $6.04 |
| Resistance Level | $16.69 | $7.52 |
| Average True Range (ATR) | 0.15 | 0.30 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 37.50 | 84.88 |
BlackRock Taxable Municipal Bond Trust is a diversified, closed-end management investment company. Its investment objective is to seek high current income, with a secondary objective of capital appreciation. The Trust seeks to achieve its investment objectives by investing in a portfolio of taxable municipal securities, including Build America Bonds (BABs), issued by state and local governments to finance capital projects such as public schools, roads, transportation infrastructure, bridges, ports and public buildings.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.